Evidence map›Paper›PMID 26687192›Full record

ArticleCancer medicine2016

Lymphovascular space invasion and lack of downstaging after neoadjuvant chemotherapy are strong predictors of adverse outcome in young women with locally advanced breast cancer.

Shariq S Khwaja, Jennifer Ivanovich, Todd A DeWees, Laura Ochoa, Daniel F Mullen, Maria Thomas, Julie A Margenthaler, Amy Cyr, Michael Naughton, Souzan Sanati and 5 more

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Saccharomyces cerevisiae-like 1 (SEC14L1) is a prognostic factor in breast cancer associated with lymphovascular invasion.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Shariq S KhwajaDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Jennifer IvanovichDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Todd A DeWeesDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Laura OchoaDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Daniel F MullenDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Maria ThomasDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Julie A MargenthalerDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Amy CyrDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Michael NaughtonDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri.
Souzan SanatiDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri.
Timothy J EberleinDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
William E GillandersDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Rebecca L AftDepartment of Surgery, Washington University School of Medicine, St. Louis, Missouri.
Jacqueline E ZoberiDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Imran ZoberiDepartment of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri.
Washington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0M
NCI NIH HHS P30 CA091842NCI NIH HHS P30CA91842
6 · The paper itself

Abstract

Younger age diagnosis of breast cancer is a predictor of adverse outcome. Here, we evaluate prognostic factors in young women with locally advanced breast cancer (LABC). We present a retrospective review of 104 patients younger than 40 years with LABC treated with surgery, radiotherapy (RT), and chemotherapy from 2003 to 2014. Patient-, tumor-, and treatment-related factors important for overall survival (OS), local/regional recurrence (LRR), distant metastasis (DM), and recurrence-free survival (RFS) were evaluated. Mean age at diagnosis was 34 years (23-39 years) with a median follow-up of 47 months (8-138 months). Breast-conserving surgery was performed in 27%. Axillary lymph node dissection was performed in 85%. Sixty percent of patients received neoadjuvant chemotherapy with 19% achieving pathologic complete response (pCR), and 61% downstaged. Lymph node positivity was present in 91% and lymphovascular space invasion (LVSI) in 35%. Thirty-two percent of patients had triple negative tumors (TN, ER-/PR-/HER2 nonamplified). Four-year OS and RFS was 84% and 71%, respectively. Factors associated with worse OS on multivariate analysis include TN status, LVSI, and number of positive lymph nodes. LVSI was also associated with DM and LRR, as well as worse RFS. Downstaging was associated with improved 4 year RFS in patients receiving neoadjuvant chemotherapy (74% vs. 38%, P = 0.002). With high risks of recurrence and inferior OS compared to older women, breast cancer in young women can be difficult to treat. Among additional factors, presence of LVSI and lack of downstaging portends a particularly worse prognosis.

Indexed as

AdultAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCombined Modality TherapyFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLymphatic MetastasisNeoplasm GradingNeoplasm InvasivenessNeoplasm StagingPrognosisRetrospective StudiesTreatment OutcomeBiomarkers, TumorBreast cancerlocally advancedLVSIneoadjuvant chemotherapyyoung women

Identifiers

PMID26687192
PMCPMC4735787
OpenAlexW2218361073

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.